Test Price
2,800 AED✅ Home Collection Available
CHKB Gene Congenital Megaconial Muscular Dystrophy Genetic Test in UAE | 2,800 AED
Executive Summary & Core Metrics
- Diagnostic Accuracy: 99.9% sensitivity for coding region variants via ISO 9001:2015 accredited NGS platform.
- Collection Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
- Post-Test Support: Complimentary telephonic clinical guidance with result interpretation by a DHA-licensed genetics specialist.
- Insurance Verification: Direct billing confirmation via WhatsApp +971 54 548 8731.
- Turnaround Time: Results delivered within 3–4 weeks from sample receipt.
Test Overview & Methodology
The CHKB gene test analyses the entire coding region of the choline kinase beta gene using Next Generation Sequencing (NGS) to detect pathogenic variants responsible for congenital megaconial muscular dystrophy — a rare, early-onset neuromuscular condition characterised by enlarged mitochondria in skeletal muscle tissue. This comprehensive molecular analysis enables definitive diagnosis, guides respiratory and nutritional management, and facilitates accurate recurrence risk counselling for affected families.
| Feature | CHKB NGS Test – DNA Labs UAE | Alternative – Sanger Sequencing |
|---|---|---|
| Methodology | NGS – full gene coverage, deep read depth, CNV detection | Single-exon Sanger sequencing only |
| Diagnostic Sensitivity | 99.9% for all coding and splice-site variants | ~95% limited to known common variants |
| Turnaround Time | 3–4 weeks | 4–6 weeks (sequential processing) |
| Sample Types Accepted | Whole Blood, Dried Blood Spot (FTA Card), Extracted DNA | Whole Blood only |
| Price (AED) | 2,800 | 2,500 – 3,200 (variable, lab-dependent) |
Physician Insight & Safety Protocols
“Congenital megaconial muscular dystrophy presents a diagnostic challenge in early childhood due to overlapping features with other congenital myopathies. This NGS-based analysis of the CHKB gene provides definitive molecular confirmation, enabling accurate prognosis, targeted respiratory and feeding support, and informed genetic counselling for the family. However, a negative result does not rule out other forms of muscular dystrophy; comprehensive clinical and histopathological correlation remains essential.”
Advisory Precautions & Medication Guidance
Medication & Clinical Advisory
Do not discontinue, alter, or initiate any prescribed therapy (including corticosteroids, respiratory support, or nutritional interventions) based solely on genetic test results. All management decisions must be supervised by the treating paediatric neurologist or metabolic specialist. Genetic findings complement but do not replace acute clinical assessment.
Exclusion Criteria & Clinical Contraindications
- Blood transfusion within 14 days prior to sample collection (may cause false negative due to donor DNA dilution).
- Current anticoagulant therapy without explicit medical clearance from the referring physician.
- Neonates requiring capillary blood draw: prior paediatric assessment is mandatory.
- Acute febrile illness, active infection, or uncontrolled bleeding disorder at time of collection.
- Inability to obtain informed consent from parent or legal guardian for minor patients.
If any of these criteria are present, please contact our clinical coordination team for guidance before proceeding with sample collection.
Patient FAQ & Clinical Guidance
1. What does the CHKB gene test diagnose and why is it clinically important?
Answer: The CHKB genetic test confirms or excludes congenital megaconial muscular dystrophy, a rare but severe neuromuscular disorder presenting in infancy or early childhood. Early molecular diagnosis prevents misdiagnosis as congenital myopathy, enables tailored respiratory and nutritional management, and provides accurate recurrence risk information for family planning. Testing is recommended when clinical features include hypotonia, proximal muscle weakness, elevated creatine kinase, and muscle biopsy showing enlarged mitochondria.
2. How is the sample collected for the CHKB genetic test in the UAE?
Answer: A certified phlebotomist visits your home between 8 AM and 11 PM (VIP Mobile Phlebotomy service) or you may attend our Dubai Healthcare City facility. Collection options include standard EDTA whole blood via venipuncture, a painless dried blood spot from a finger or heel prick (preferred for infants), or submission of previously extracted DNA. All samples are transported under ISO-certified temperature-controlled cold chain to our CAP-accredited laboratory in Dubai.
3. How long do results take and how are they clinically verified?
Answer: Results are delivered within 3 to 4 weeks from sample receipt. Our NGS workflow includes stringent bioinformatic filtering against ClinVar, gnomAD, and HGMD databases. All variants are classified according to ACMG/AMP guidelines. The final report is reviewed and signed by a DHA-licensed Consultant Medical Genetics specialist, and you receive a complimentary teleconsultation to discuss findings and recommended follow-up steps.
4. Can this test detect carriers or be used for prenatal diagnosis?
Answer: Yes, the CHKB NGS test accurately identifies heterozygous carriers with 99.9% sensitivity, making it suitable for at-risk family member screening. For prenatal diagnosis, a separate invasive procedure (chorionic villus sampling or amniocentesis) is required. Please discuss with our genetics team to coordinate the appropriate workflow and consent process.
5. What are the emergency signs that require immediate medical attention?
Answer: Seek urgent medical care if the patient experiences sudden difficulty breathing, cyanosis (blue discolouration of lips or skin), severe muscle weakness affecting swallowing or head control, loss of consciousness, cardiac rhythm irregularities, or unexplained worsening of muscle tone or new-onset seizures. Genetic testing does not replace emergency clinical management.
UAE Regulatory & Data Privacy Adherence
Data Protection & Health Information Governance: All patient data and genetic results are processed in strict compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing safety, patient consent, and medical liability procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. DNA Labs UAE is ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139) and holds DHA Facility License No. 1143.
Patient Rights: You have the right to access, rectify, and request deletion of your personal data. Informed consent is obtained for all genetic analyses. Results are shared only with the ordering physician and the patient or legal guardian. For any privacy-related queries, contact our Data Protection Officer at +971 54 548 8731.
Clinical & Logistical Metadata
| Test Name | CHKB Gene Congenital Megaconial Muscular Dystrophy Genetic Test (NGS) |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA), Dried Blood Spot (FTA Card), Extracted DNA |
| Methodology Used | Next Generation Sequencing (NGS) – full gene coverage with CNV analysis |
| ICD-10-CM Code | G71.2 |
| LOINC Code | 94856-0 |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians